 |
| Prof Andrew Spencer explains the research in this video: www.youtube.com/watch?v=spfbhnn1Nhc |
Professor Andrew Spencer, of the Australian Centre for Blood Diseases, recently received funding under the Medical Research Future Fund (MRFF) of $1.68M for a trial in elderly Multiple Myeloma (MM) patients to investigate treatment options. The full title of his study is "Frailty-stratified randomised controlled bayesian adaptive trial of bortezomib versus lenalidomide in transplant-ineligible myeloma - the FRAIL-M study". In this video he explains the significance of the research.
